178 related articles for article (PubMed ID: 35736670)
1. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Thompson MC; Harrup RA; Coombs CC; Roeker LE; Pu JJ; Choi MY; Barr PM; Allan JN; Šimkovič M; Leslie L; Rhodes J; Chong EA; Kamdar M; Skarbnik A; Lansigan F; McCall B; Saja K; Dyer MJS; Walter HS; Lefebure M; Thadani-Mulero M; Boyer M; Biondo J; Sail K; Manzoor BS; Furman R; Bantilan KS; Goy A; Feldman T; Labella D; Schuster SJ; Park J; Palomba L; Zelenetz A; Eyre TA; Kater AP; Seymour JF; Mato AR
Blood Adv; 2022 Aug; 6(15):4553-4557. PubMed ID: 35736670
[No Abstract] [Full Text] [Related]
2. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
3. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
4. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
5. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A; Mauro FR; Scarfò L; Gentile M; Farina L; Reda G; Ferrarini I; Proietti G; Derenzini E; Cibien F; Vitale C; Sanna A; Pietrasanta D; Marchetti M; Murru R; Rigolin GM; Sportoletti P; Trimarco V; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Zatta I; Laurenti L; Molica S; Coscia M; Ghia P; Foà R; Cuneo A; Trentin L
Am J Hematol; 2023 Sep; 98(9):E237-E240. PubMed ID: 37382471
[No Abstract] [Full Text] [Related]
6. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
9. Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective.
Sönmez M; Kestane M; Akıdan O; Erkut N; Bektaş Ö
Turk J Haematol; 2021 Dec; 38(4):344-346. PubMed ID: 34792306
[No Abstract] [Full Text] [Related]
10. Venetoclax Yields Strong Responses in CLL.
Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Jiang R; Dai LMJ; Sha YQ; Xia Y; Miao Y; Qin SC; Wu W; Qiu JY; Bi HL; Wang L; Fan L; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):247-250. PubMed ID: 37356988
[No Abstract] [Full Text] [Related]
13. Emerging data for venetoclax in chronic lymphocytic leukemia.
O'Brien SM
Clin Adv Hematol Oncol; 2022 Mar; 20(3):178-183. PubMed ID: 36607348
[No Abstract] [Full Text] [Related]
14. Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929430
[No Abstract] [Full Text] [Related]
15. Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
Robak E; Jesionek-Kupnicka D; Stelmach P; Kupnicki P; Szataniak M; Robak T
Ann Hematol; 2022 Jun; 101(6):1387-1392. PubMed ID: 35187604
[No Abstract] [Full Text] [Related]
16. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
17. Acquired Pelger-Huet anomaly in two patients with chronic lymphocytic leukemia treated with venetoclax.
Robier C; Knaus G; Egger M
Clin Chem Lab Med; 2021 Sep; 59(10):e395-e397. PubMed ID: 33984884
[No Abstract] [Full Text] [Related]
18. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
19. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
20. [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].
Zou HS; Yi SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):783-787. PubMed ID: 33113617
[No Abstract] [Full Text] [Related]
[Next] [New Search]
